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Abstract. Photodynamic therapy (PDT) exerts direct cytotoxic 
effects on tumor cells, destroys tumor blood and lymphatic 
vessels and induces local inflammation. Although PDT trig-
gers the release of immunogenic antigens from tumor cells, 
the degree of immune stimulation is regimen-dependent. The 
highest immunogenicity is achieved at sub-lethal doses, which 
at the same time trigger cytoprotective responses, that include 
increased expression of glucose-regulated protein 78 (GRP78). 
To mitigate the cytoprotective effects of GRP78 and preserve 
the immunoregulatory activity of PDT, we investigated the 
in vivo efficacy of PDT in combination with EGF-SubA cyto-
toxin that was shown to potentiate in vitro PDT cytotoxicity by 
inactivating GRP78. Treatment of immunocompetent BALB/c 
mice with EGF-SubA improved the efficacy of PDT but only 
when mice were treated with a dose of EGF-SubA that exerted 
less pronounced effects on the number of T and B lympho-
cytes as well as dendritic cells in mouse spleens. The observed 
antitumor effects were critically dependent on CD8+ T cells 
and were completely abrogated in immunodeficient SCID 
mice. All these results suggest that GRP78 targeting improves 
in vivo PDT efficacy provided intact T-cell immune system.
Introduction
Photodynamic therapy (PDT) is an approved anticancer treat-
ment, which involves systemic or local administration of a 
photosensitizer (PS) followed by illumination of the tumor 
with visible light. In the presence of oxygen it generates reac-
tive oxygen species (ROS), which exert direct cytotoxic effects 
on tumor cells, as well as on the tumor vasculature (1). PDT 
leads to a significant decrease or elimination of the primary 
tumor. However, for long-term efficacy of PDT, the intact 
immune response is essential (2). It was demonstrated that in 
immunocompromised animals devoid of adaptive immunity, 
PDT initially triggers tumor ablation, but permanent cures are 
not observed (3). Specific depletion of selected populations of 
leukocytes revealed that neutrophils and CD8+ T cells play an 
indispensable role in achieving maximum therapeutic effects 
of PDT (4). Further studies confirmed that PDT generates 
damage-associated molecular pattern (DAMP) proteins and 
that PDT-triggered cell death is associated with immunogenic 
antigens (5,6). However, induction of the immune response by 
PDT depends primarily on the treatment regimen as well as 
on the tumor model. It was demonstrated that low-dose PDT 
stimulates an inflammatory response better than high-dose 
PDT, both in mice (7) and in clinical settings (8). A number of 
approaches to enhance the immune response triggered by PDT 
have been proposed, including combinations with immune-
stimulating agents (9,10).
On the other hand, the sub-lethal PDT doses, optimal 
for immune stimulation, are usually insufficient to eradicate 
primary tumor due to induction of cytoprotective responses. 
To counterbalance PDT-triggered oxidative stress, tumor 
cells upregulate ROS-scavenging enzymes, stress-related 
transcription factors and chaperones. Moreover, the accumula-
tion of misfolded proteins in the endoplasmic reticulum (ER) 
triggers unfolded protein response (UPR). It was shown that 
PDT induces expression of the master regulator of the UPR, 
glucose regulated protein 78 (GRP78) (11,12). GRP78 is an 
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endoplasmic reticulum resident chaperone, which is highly 
expressed in tumor cells. Increasing number of studies reveals 
that this protein is upregulated in response to various therapies 
and contributes to treatment resistance (13). Therefore, attempts 
to inhibit GRP78 are considered as components of anticancer 
therapy. In contrast to several small-molecule GRP78 inhibi-
tors, which are very unspecific, a bacterial subtilase cytotoxin 
(Sub) has been shown to specifically cleave and inactivate 
GRP78 (14). The holotoxin (SubAB5) produced by Shiga 
toxigenic strains of Escherichia coli (STEC), is composed 
of a catalytic A subunit (SubA) and a pentameric B subunit, 
enabling cell entry. Previous research has revealed that the 
toxin is the major cause of hemolytic uremic syndrome, the 
most common form of the disease observed in humans infected 
with STEC. It is also lethal in mice, as it triggers substan-
tial systemic abnormalities due to microvascular damage, 
thrombosis and hemorrhage in several organs, including the 
kidneys, brain, and liver (15). Further study has shown that 
the toxin also affects the immune system, which is manifested 
by spleen atrophy and profound leukocyte redistribution (16). 
Moreover, sub-lethal doses of SubAB5 exert anti-inflammatory 
effects (17). To exploit the antitumor activity of the toxin via 
GRP78 targeting, as well as to minimize severe toxic effects, 
the fusion protein composed of epidermal growth factor (EGF) 
and the catalytic A subunit of the toxin (EGF-SubA) was 
generated for targeted toxin delivery. EGF-SubA selectively 
killed EGF receptor (EGFR)-expressing tumor cells and had 
an antitumor efficacy in a mouse model. Moreover, EGF-SubA 
synergized with UPR-inducing agents such as tunicamycin or 
thapsigargin (18).
We recently found that the expression of GRP78 was induced 
in vitro by Photofrin-PDT in human cancer cell lines and that 
GRP78 plays a cytoprotective role. Moreover, siRnA-mediated 
downregulation of GRP78 as well as EGF-SubA-mediated 
specific cleavage of GRP78, sensitized tumor cells to in vitro 
PDT (19). Here, we investigated the combination of EGF-SubA 
with PDT in vivo in mouse models.
Materials and methods
Reagents. Photofrin (Axcan Pharma Inc., Houdan, France) 
was used as a photosensitizer. Photofrin was dissolved in 
5% glucose, aliquoted and stored at -20˚C. EGF-SubA fusion 
protein was purchased from SibTech Inc. (Brookfield, CT, 
USA). The 0.75 µM (in vitro studies) or 1 mg/ml (in vivo 
studies) stock solutions were aliquoted and stored at -20˚C.
Cell culture. Mouse colon carcinoma (CT26) and human 
prostate cancer (DU-145) cell lines were purchased from the 
American Type Culture Collection (ATCC; Rockville, MD, 
USA). Cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium (CT26) or Dulbecco's modified Eagle's 
medium (DMEM) (DU-145) supplemented with 20% (CT26) 
or 5% (DU-145) heat-inactivated fetal bovine serum (Hyclone) 
and antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, 
MO, USA). Cells were cultured under standard conditions in a 
5% CO2 humidified incubator at 37˚C.
Generation of CT26 cells stably expressing human EGFR. A 
CT26 cell line stably expressing human EGFR (CT26-EGFR) 
was generated using a retroviral system. HEk 293T cells were 
co-transfected with the pBabe-EGFR-puro plasmid, packaging 
pkAT and envelope pVSV-G vectors using a calcium chloride 
protocol. The pBabe-EGFR-puro plasmid encoding WT 
human EGFR was a gift from Matthew Meyerson (plasmid 
#11011; Addgene) (20). Twenty-four hours post-transfection, 
medium from the HEk 293T cells was collected, centri-
fuged and filtered through a 0.45-µm filter. Afterwards, the 
CT26 cells were added to retrovirus-containing medium and 
centrifuged for 1 h (500 x g, RT) in the presence of 12 µg/
ml Polybrene (Sigma-Aldrich). next, the cells were selected 
with 10 µg/ml puromycin (Sigma-Aldrich) and sorted for 
high EGFR expression with cell sorter FACSAria III (Becton 
Dickinson). The overexpression of EGFR was confirmed by 
flow cytometry and western blotting.
Cell viability assay. In order to evaluate the cytostatic/cyto-
toxic effect of EGF-SubA on cancer cells, 1.25x103 cells/well 
were plated onto 96-well plates, incubated with increasing 
concentrations of EGF-SubA for 48 h and stained with crystal 
violet as described previously (21).
Flow cytometry and cell sorting. To confirm the presence of 
EGFR on the cell surface, the cells were trypsinized, pelleted, 
washed with PBS and blocked in 1% BSA for 15 min. next, 
the cells were incubated with chimeric anti-EGFR antibody 
(Erbitux) for 40 min (1:50) followed by incubation with 
anti-human IgG-Alexa488 antibody (1:100, 30 min; Jackson 
ImmunoResearch). The cells were analyzed by FACScan 
(Becton Dickinson) using CellQuest Pro software version 5.2. 
To select the EGFR-expressing population, the CT26 cells 
were stained for surface EGFR as described and Alexa488-
positive cells were sorted for using FACSAria III (Becton 
Dickinson).
Splenocyte isolation and analysis of leukocyte populations. 
Spleens were isolated from mice of each experimental group. 
To obtain a single-cell suspension, the spleens were forced 
through a 70-µm cell strainer. To lyse erythrocytes, the cells 
were incubated for 5 min at 37˚C in red blood cell lysis buffer 
(150 mM nH4Cl, 1 mM naHCO3, pH 7.4). next, the cells were 
washed with PBS and resuspended in RPMI-1640 medium 
containing 10% fetal bovine serum.
To determine the total splenocyte count, the cells were 
stained with anti-CD45 antibody and the number of viable 
cells in 10 µl was determined using the Accuri C6 flow 
cytometer (Becton Dickinson). To evaluate leukocyte popu-
lations, the splenocytes were stained with the following 
monoclonal antibodies (mAbs): anti-B220-eFluor® 450 (REF. 
48-0452-80), anti-CD3-PE-Cy7 (REF. 25-0031-82), anti-
CD4-APC (REF. 17-0041), anti-CD8-FITC (REF. 11-0081), 
anti-CD11c-eFluor® 450 (REF. 48-0114) (all from eBioscience) 
anti-CD45.2-BD HorizonBD Horizon™ V500 (REF. 562129; 
BD Biosciences), anti-MHCII-PE-Cy7 (REF. 25-5321; eBio-
science) and analyzed using FACSAria III.
Western blotting. Cells were pelleted and lysed in a lysis buffer 
(50 mM HEPES pH 7.4, 1.0% Triton x-100, 150 mM naCl, 
10% glycerol, 5 mM EDTA) supplemented with Complete 
protease inhibitors (Roche, Mannheim, Germany) and phos-
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phatase inhibitors (1 mM sodium ortho-vanadate, 1 mM 
sodium fluoride, and 1 mM 2-glycerol phosphate). The protein 
concentration was measured using the Bio-Rad protein assay 
(Bio-Rad, Hercules, CA, USA). Equal amounts of proteins were 
separated by SDS-PAGE and transferred to Protran® nitrocel-
lulose membranes (Schleicher and Schuell BioScience, Dassel, 
Germany). The membranes were blocked and incubated with 
the following primary antibodies (GRP78-3183; Cell Signaling 
Technology, Beverly, MA, USA; β-actin-A3854; Sigma-
Aldrich) according to the manufacturer's protocols. After 
extensive washing with TBST, the membranes were incubated 
for 40 min with HRP-linked secondary antibodies (Cell 
Signaling Technology). The chemiluminescence reaction was 
developed using self-made reagent (50 mM Tris-HCl pH 8.5, 
0.2 mM cumaric acid, 1.25 mM luminol, 0.006% hydrogen 
peroxide) and visualized with Stella 8300 Bio-imager (Raytest, 
Straubenhardt, Germany).
Mice. For the in vivo experiments 8- to 14-week-old female 
BALB/c or SCID mice were used. BALB/c mice were obtained 
from the Animal House of the Polish Academy of Sciences, 
Medical Research Center (Warsaw, Poland). SCID mice were 
obtained from Charles River Laboratory (Erkrath, Germany). 
The experiments were performed in accordance with the 
guidelines approved by the Ethics Committee of the Medical 
University of Warsaw.
PDT in vivo. Before inoculation, the cells were harvested, 
washed twice and resuspended with PBS (CT26-EGFR) or 
PBS with 25% Matrigel (DU-145). The viability of the cells 
was determined by trypan blue staining. A total of 3x105 CT26-
EGFR cells (in 30 µl) or 2x106 of DU-145 cells (in 100 µl) were 
injected subcutaneously into the right thigh of the experimental 
mice (day 0). On days 6-8 (BALB/c) or 7-9, the (SCID) mice 
were injected intraperitoneally (i.p.) with EGF-SubA (25 or 
50 µg/kg) in PBS. Photofrin was administered i.p. at a dose 
of 10 mg/kg on day 6 (BALB/c) or day 7 (SCID). Twenty-four 
hours later, the tumors were illuminated with 630 nm light 
delivered by a He-ne ion laser (Laserinstruments, Warsaw, 
Poland) through optical fibre. The power of the laser was 
45-47 mW/cm2 and the total fluence was 50 J/cm2 for CT26 
and 43 J/cm2 for DU-145 cells. During the time of illumina-
tion, the mice were anesthetized with ketamine and xylazine 
and restrained. Tumor growth was monitored 3 times a week 
(BALB/c) or once a week (SCID) with the use of a caliper, as 
described previously (22). The mice were sacrificed when any 
of the tumor diameters reached 15 mm.
Depletion. Mice were injected i.p. with 100 µg of anti-CD8 
(yTS169) monoclonal antibodies (mAbs) on days 5 and 11 
of the experiment. Control mice received 100 µg of isotype 
control mAb. The level of depletion was evaluated 3 days after 
mAb injection. Blood samples were collected from the jugular 
vein of the experimental mice, stained with the anti-CD8 mAb 
and analyzed by flow cytometry.
Histopathologic analysis. After animal sacrifice, livers, 
spleens and kidneys were removed and fixed in buffered 4% 
formaldehyde for 48 h at RT. Subsequently, the tissue samples 
were dehydrated through a series of graded ethanol baths to 
displace the water, cleared in xylene, infiltrated with paraffin 
wax and then embedded in paraffin blocks. Paraffin sections 
Figure 1. EGF-SubA exerts cytostatic/cytotoxic effects on CT26 cells 
expressing human EGFR. (A) CT26 cells were infected with retroviruses 
containing human EGFR and sorted for high expression of surface EGFR. 
The level of expression was confirmed by flow cytometry. (B) CT26-EGFR 
cells were plated onto 60-mm dishes and incubated for 48 h with different 
concentrations of EGF-SubA. The amounts of GRP78 protein and the 
46-kDa GRP78 cleavage product (cl-GRP78) were evaluated by western 
blotting. Actin was used as a loading control. (C) CT26-EGFR and CT26 WT 
cells were plated onto a 96-well plate and incubated for 48 h with increasing 
concentrations of EGF-SubA. The viability of the cells was determined by 
crystal violet staining.
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were subsequently stained with hematoxylin and eosin (H&E). 
All tissue sections were examined using light microscopy.
Statistical analyses. Differences in tumor volumes were 
analyzed for significance by the Mann-Whitney test with 
significance level set at P<0.05. For ex vivo studies significance 
was calculated by the Mann-Whitney test. The survival rate of 
the animals was analyzed for significance by log-rank survival 
analysis. Significance was defined as a two-sided P<0.05.
Results
EGF-SubA exerts cytostatic/cytotoxic effects on CT26 cells 
expressing human EGFR. We previously observed that 
EGF-SubA potentiated the cytotoxic effects of PDT in various 
human cancer cell lines in vitro (19). In order to study the effects 
of a combination of PDT and EGF-SubA in vivo, we generated 
a murine cell line CT26 expressing human EGFR (CT26-
EGFR). The presence of EGFR on the surface of the CT26 
cells was confirmed by flow cytometry (Fig. 1A). To determine 
the efficacy of EGF-SubA, CT26-EGFR cells were incubated 
with increasing concentrations of the cytotoxin and tested for 
its ability to cleave GRP78 and to exert cytostatic/cytotoxic 
effects. Treatment with EGF-SubA resulted in accumulation of 
the GRP78 cleavage product (Fig. 1B). Moreover, the expres-
sion of EGFR sensitized CT26 cells to EGF-SubA as shown in 
the crystal violet cell viability assay (Fig. 1C).
Effects of EGF-SubA on murine immune cells and organs. 
Considering that an intact immune system is essential for PDT 
efficacy and that previous studies have described the impact 
of the SubAB5 holotoxin on immune cells, we investigated 
whether similar effects could be observed in mice treated with 
EGF-SubA. BALB/c mice were treated with 25 or 50 µg/kg 
of EGF-SubA for three consecutive days. Twenty-four hours 
after the last dose administration, spleens were collected, 
total numbers of splenocytes were counted and cells were 
analyzed by flow cytometry. We observed that a lower dose of 
EGF-SubA did not affect the immune cells, whereas the higher 
dose significantly reduced the numbers of B cells (B220+) 
and cytotoxic (CD8+) and helper (CD4+) T cells, as well as 
dendritic cells (MHCII+CD11c+) (Fig. 2).
Moreover, livers, spleens and kidneys were removed after 1, 
2 and 3 doses of EGF-SubA and analyzed histopathologically. 
In mice treated with 25 µg/kg EGF-SubA, we occasionally 
observed hemorrhagic foci and hepatic necrosis as well as 
Figure 2. EGF-SubA affects immune cells. EGF-SubA at a dose of 25 or 
50 µg/kg was administered i.p. for three consecutive days. Twenty-four 
hours after the last injection, mouse spleens were collected, total numbers 
of splenocytes were counted and analyzed by flow cytometry. Total numbers 
of cytotoxic (A) and helper (B) T cells, dendritic cells (C), B cells (D), and 
total leukocytes (E) were calculated. n=7 (control group), n=8 (25 and 50 µg/
kg). *P<0.05, **P<0.01, ***P<0.005 compared with the control group (Mann-
Whitney test).
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very subtle changes in spleens and kidneys (data not shown). 
More pronounced changes were observed in the mice treated 
with 50 µg/kg of EGF-SubA. Splenic abnormalities included 
small accumulations of reticular fibers in the white pulp; renal 
abnormalities ranged from subtle edematous changes in deep 
cortical layer tubules to more pronounced focal deposits of 
eosinophilic material in some tubules, with obliteration of their 
lumina. The most noticeable changes we observed in the livers 
of mice treated with 50 µg/kg of EGF-SubA (Fig. 3). After one 
or two doses of the toxin we observed pronounced hepatocyte 
anisocytosis and occasional hemorrhagic foci. Hepatocytes 
located adjacent to the periportal areas were denser, whereas 
those located around central veins were edematous with pale 
cytoplasm. After three doses of EGF-SubA, vesicular fatty 
changes predominated in the cytoplasm of hepatocytes located 
in centrilobular areas. Moreover, isolated foci of necrosis and 
hemorrhagic changes were also visible with occasional areas 
of hepatocyte anisocytosis. Altogether, we observed that a 
50 µg/kg dose of EGF-SubA negatively affected the immune 
cells and triggered histopathological changes.
EGF-SubA improves PDT efficacy. To determine whether 
EGF-SubA is able to potentiate the antitumor effects of PDT 
in vivo, we used the CT26-EGFR cell line. BALB/c mice 
subcutaneously injected with the CT26-EGFR cells were 
treated with PDT on day 7 after inoculation of tumor cells and 
EGF-SubA was administered at a dose of 25 µg/kg for three 
consecutive days (days 6-8) (Fig. 4A). We observed that the 
combination treatment resulted in a trend towards decreased 
tumor size (Fig. 4B) as well as prolonged survival (Fig. 4C), 
as compared with PDT alone. The difference in survival 
of mice treated with PDT only and PDT in combination 
with EGF-SubA was noticeable, and close to statistical 
significance (P=0.067, log-rank test). These effects were not 
observed in the mice treated with a higher dose (50 µg/kg) of 
EGF-SubA (Fig. 4D and E).
A functional immune system is necessary for the effects 
of the combination treatment. All the above data suggest 
that a functional immune response is essential for the final 
outcome of the combination treatment. In order to confirm this 
hypothesis, we performed the combination treatment in mice 
depleted of CD8+ cells, which have been shown essential for 
immune effects of PDT (Fig. 5A) (4). Depletion of CD8+ cells 
in the BALB/c mice completely abrogated the effects of the 
combination treatment on tumor size (Fig. 5B). Furthermore, 
no complete responses were observed in the CD8+-depleted 
mice (Fig. 5C).
To further confirm that the functional immune system is 
crucial for the efficacy of PDT + EGF-SubA treatment, we 
aimed to determine whether the combination could be effec-
tive in immunocompromised mice. Previously, we observed 
a strong potentiation of in vitro cytostatic/cytotoxic effects 
of PDT in the human prostate cancer cell line DU-145 (19). 
Therefore, SCID mice were subcutaneously injected with 
DU-145 cells and treated with PDT on day 8 after inocula-
tion of tumor cells and with EGF-SubA at a dose of 25 µg/kg 
for three consecutive days (days 7-9) (Fig. 6A). Treatment of 
DU-145 tumors with PDT resulted in the prolonged survival of 
SCID mice, however, no complete responses were observed. 
Despite the initial mild effects on tumor growth (Fig. 6B), the 
addition of EGF-SubA to the PDT protocol did not influence 
mouse survival in this model (Fig. 6C).
Discussion
The clinical application of PDT in cancer treatment is still 
limited to a small number of indications. However, the undeni-
able feature of PDT is its potential to elicit a specific antitumor 
immune response. Importantly, the ability of local PDT to 
induce systemic antitumor immunity has been demonstrated 
in patients with basal cell carcinoma (8). However, the degree 
of immune response induction by PDT is variable, regimen-
Figure 3. EGF-SubA causes pathological changes in murine livers. Hematoxylin and eosin-stained liver sections from control and 50 µg/kg EGF-SubA-treated 
mice, scale bars A, C, E and G = 250 µm; B, D, F and H = 125 µm. (A and B) Periportal area (centrilobular area) of control liver. (C) Hepatocytes with various 
densities of cytoplasm; the white arrow indicates the area around a central vein; the black arrow indicates the periportal area. (D) A higher magnification of the 
area around a central vein. (E) An area of hemorrhagic foci and necrosis are indicated with white and black arrows, respectively. (F) Dispersed lymphocytic 
infiltration. (G and H) necrosis with erythrocytes, marked with arrows.
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dependent and in the majority of models insufficient to cure 
cancer. Paradoxically, the most immune-stimulatory regimens 
are concomitantly sub-cytotoxic and the overall PDT effect 
is insufficient to obtain long-term responses. Therefore, 
the continuous search for treatment modalities combining 
PDT with other antitumor agents is warranted. notably, our 
previous in vitro study in human cancer cell lines revealed a 
strong synergism between PDT and EGF-SubA cytotoxin (19).
Here, we showed that a low dose of EGF-SubA, the cytotoxin 
that cleaves and inactivates the master ER chaperone GRP78, 
increased the efficacy of PDT in vivo in immunocompetent 
mice. However, the antitumor effects were critically dependent 
on a functional immune response. Firstly, the antitumor effects 
were observed for the low (25 µg/kg), and not for the high 
(50 µg/kg) EGF-SubA dose (Fig. 4). Administration of the latter 
strongly depleted immune cells such as CD8+ and CD4+ T cells, 
B cells and dendritic cells in the spleens of mice. These effects 
were not observed in animals treated with the low EGF-SubA 
dose (Fig. 2). Secondly, the depletion of CD8+ T cells with 
monoclonal antibodies entirely abolished the antitumor effects 
of the combination treatment on both tumor growth rate and 
animal survival, supporting the fundamental contribution of 
these cells to the treatment outcome (Fig. 5B and C). Finally, 
in immunocompromised mice devoid of adaptive immunity, 
although the tumor-suppressive effect of both PDT alone 
as well as PDT with EGF-SubA were evident in a few days 
following PDT, none of the therapies were effective in the 
long run (Fig. 6B and C). All these results demonstrated that 
the combination of PDT with EGF-SubA may be effective 
providing an intact immune response.
Our results support previous findings that the immune 
response is crucial for overall PDT efficacy (3,23). The role 
of selected immune cell populations in the PDT-induced anti-
tumor immune response was extensively studied in various 
experimental models over the last two decades. Our results, 
as the majority of other reports (4,10,24), substantiate the role 
of CD8+ T cells as critically important players in the mainte-
nance of durable PDT-induced curative effects. Moreover, we 
observed that both the depletion of CD8+ T cells (Fig. 5) as 
well as the decrease in a number of CD8+ T cells and other 
immune cells in the spleens of mice treated with a higher dose 
of EGF-SubA (Fig. 2), negatively affected PDT efficacy. These 
Figure 4. EGF-SubA at a dose of 25 µg/kg potentiates the antitumor effects of PDT in BALB/c mice injected with CT26-EGFR cells. (A) Mice were inoculated 
with 3x105 CT26-EGFR cells. On days 6-8 mice were treated with EGF-SubA at a dose of 25 µg/kg (B and C) or 50 µg/kg (D and E). Photofrin was adminis-
tered i.p. at a dose of 10 mg/kg on day 6. Twenty-four hours later, the tumor site was illuminated with laser light at a fluence of 50 J/cm2. (B and D) Mean tumor 
volumes (±SE). Experiments were performed twice (EGF-SubA 25 µg/kg) or once (EGF-SubA 50 µg/kg). One representative result is shown for EGF-SubA 
25 µg/kg (n=7-8 for all experimental groups). (C and E) kaplan-Meyer plots of the survival of the mice bearing CT26-EGFR tumors. The overall survival from 
two combined independent experiments is shown for EGF-SubA 25 µg/kg (n=12). P=0.067 (PDT + EGF-SubA compared to all other groups, log-rank test). 
n=5-6 in all experimental groups in the EGF-SubA 50 µg/kg group.
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results are in line with previous findings that a combination of 
a high dose of cyclophosphamide, which decreases the number 
of splenocytes, reduced the survival of mice and impaired PDT 
efficacy (25). Collectively these results imply that a disturbance 
of the immune response may have detrimental impact on the 
overall PDT effects and may have important implications for 
the evaluation of novel agents in combination with PDT.
Another important finding was that EGF-SubA cytotoxin 
at sub-lethal doses affects the immune system. EGF-SubA is 
a fusion protein composed of EGF and a catalytic subunit of 
the holotoxin SubAB5, and was designed to selectively target 
EGFR-overexpressing tumor cells. Backer et al (18) demon-
strated that the EGF-SubA fusion protein selectively kills 
tumor cells expressing EGFR and suppresses the growth of 
Figure 5. The efficacy of the combination treatment is dependent on CD8+ T cells. (A) BALB/c mice were inoculated with 3x105 CT26-EGFR cells. On 
days 6-8, the mice were treated with EGF-SubA at a dose of 25 µg/kg. Photofrin was administered i.p. at a dose of 10 mg/kg on day 6. Twenty-four hours later, 
the tumor site was illuminated with laser light at fluence of 50 J/cm2. On days 5 and 11, the mice were injected i.p. with 100 µg of anti-CD8 (yTS169) mAbs or 
a control antibody. (B) Mean tumor volumes (±SE). The experiment was repeated twice and a representative result is shown. Depl (depletion) describes group 
of mice treated with depleting mAbs and iso refers to the group treated with isotype control mAbs (n=6 for control iso and control depl, n=5 for PDT + EGF-
SubA iso and n=8 for PDT + EGF-SubA depl). (C) kaplan-Meyer plots of the survival of the mice bearing CT26-EGFR tumors. The overall survival from 
two combined independent experiments is shown (n=12-13). *P<0.05 compared with all experimental groups (Mann-Whitney test). #P<0.001 compared with 
all experimental groups (log-rank test).
Figure 6. EGF-SubA + PDT treatment is ineffective in immunocompromised mice. (A) SCID mice were inoculated with 2x106 of DU-145 cells. On days 7-9, 
the mice were treated i.p with EGF-SubA (25 µg/kg) in PBS. Photofrin was administered i.p. at a dose of 10 mg/kg on day 7. Twenty-four hours later, the tumor 
site was illuminated with laser light at fluence of 43 J/cm2. (B) Mean tumor volumes (±SE). The experiment was performed once. (C) kaplan-Meyer plots of 
the survival of the mice bearing DU-145 tumors (n=7-8). 
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these tumors in vivo at a dose of 125 µg/kg, without observ-
able toxic effects. In our experimental settings, doses of 
EGF-SubA exceeding 100 µg/kg were already toxic, leading 
to the deaths of approximately half of the treated animals after 
two administrations of the fusion protein (data not shown). 
The difference may result from various dosing schedules. The 
lower EGF-SubA dose, 50 µg/kg, did not trigger any lethal 
effects, yet it decreased the numbers of immune cells in the 
spleens of treated animals (Fig. 2). Moreover, the histopatho-
logical examinations of the livers of mice treated with 50 µg/
kg EGF-SubA revealed the presence of necrotic and hemor-
rhagic foci (Fig. 3). These observations are reminiscent of the 
effects reported in mice treated with SubAB5 holotoxin (16). 
Several possible explanations exist as to how the fusion protein 
affects cells not expressing EGFR. It may be transmitted to 
immune cells via endocytosis together with dying tumor cells. 
Alternatively, the EGF-SubA fusion protein tropism may 
not be restricted to EGFR-expressing cells, especially when 
administered at higher doses.
In summary, we showed that GRP78-targeting EGF-SubA 
cytotoxin improves the efficacy of PDT in vivo, but only at a 
lower dose which does not impair the immune system. Our 
results further substantiate the indispensable role of the adap-
tive immunity in achieving long-term curative PDT effects.
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